Introduction to expert opinion on endocrine complications of new anticancer therapies.

导出 LinkOut

翻译打印收藏纠错

第一作者： Frederic,Castinetti

第一单位： Aix-Marseille University, INSERM, U1251, Marseille Medical Genetics, and Department of Endocrinology, La Conception Hospital, Assistance Publique-Hopitaux de Marseille, 13005 Marseille, France. Electronic address: Frederic.CASTINETTI@ap-hm.fr.

作者： Frederic,Castinetti ^[1] ; Françoise,Borson-Chazot ^[2]

作者单位： Aix-Marseille University, INSERM, U1251, Marseille Medical Genetics, and Department of Endocrinology, La Conception Hospital, Assistance Publique-Hopitaux de Marseille, 13005 Marseille, France. Electronic address: Frederic.CASTINETTI@ap-hm.fr. ^[1] Fédération d'Endocrinologie, Hospices Civils de Lyon, université Claude-Bernard Lyon 1, HESPER EA 7425, 69008 Lyon, France. ^[2]

关键词 CTLA-4 Immunotherapy MTOR inhibitors PD-1 PD-L1 Tyrosine kinase inhibitors

主题词动物(Animals);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);多数赞同(Consensus);内分泌系统疾病(Endocrine System Diseases);人类(Humans);免疫疗法(Immunotherapy)

DOI 10.1016/j.ando.2018.07.001

PMID 30056976

发布时间 2019-02-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交